Literature DB >> 19457834

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Seong Hyun Kim1, Seung Hoon Kim, Jongmee Lee, Min Ju Kim, Yong Hwan Jeon, Yulri Park, Dongil Choi, Won Jae Lee, Hyo K Lim.   

Abstract

OBJECTIVE: We compared the diagnostic performance of gadoxetic acid-enhanced MRI with that of triple-phase 16-, 40-, and 64-MDCT in the preoperative detection of hepatocellular carcinoma (HCC). SUBJECTS AND METHODS: Sixty-two consecutively registered patients (54 men, eight women; age range, 31-67 years) with 83 HCCs underwent triple-phase (arterial, portal venous, equilibrium) CT at 16-, 40-, or 64-MDCT and gadoxetic acid-enhanced 3-T MRI. The diagnosis of HCC was established after surgical resection. Three observers independently and randomly reviewed the MR and CT images on a tumor-by-tumor basis. The diagnostic accuracy of these techniques in the detection of HCC was assessed with alternative free response receiver operating characteristic (ROC) analysis. Sensitivity, positive and negative predictive values, and sensitivity according to tumor size were evaluated.
RESULTS: For each observer, the areas under the ROC curve were 0.971, 0.959, and 0.967 for MRI and 0.947, 0.950, and 0.943 for CT. The differences were not statistically significant between the two techniques for each observer (p > 0.05). The differences in sensitivity and positive and negative predictive values between the two techniques for each observer were not statistically significant (p > 0.05). Among 10 HCCs 1 cm in diameter or smaller, each of the observers detected seven tumors with MRI. With CT, one observer detected five, one observer detected four, and one observer detected three HCCs with no statistically significant difference (p > 0.05).
CONCLUSION: Gadoxetic acid-enhanced MRI and triple-phase MDCT have similar diagnostic performance in the preoperative detection of HCC, but MRI may be better than MDCT in the detection of HCC 1 cm in diameter or smaller.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457834     DOI: 10.2214/AJR.08.1262

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  101 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population.

Authors:  Min Jung Park; Young-Sun Kim; Won Jae Lee; Hyo K Lim; Hyunchul Rhim; Jongmee Lee
Journal:  Eur Radiol       Date:  2010-06-19       Impact factor: 5.315

3.  3.0 Tesla magnetic resonance imaging: A new standard in liver imaging?

Authors:  Rossano Girometti
Journal:  World J Hepatol       Date:  2015-07-28

4.  Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Junji Shiraishi; Kazuhiro Saito; Junichi Taira; Toru Saguchi; Yasuharu Imai
Journal:  Eur Radiol       Date:  2012-01-24       Impact factor: 5.315

5.  Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI.

Authors:  H Rhee; M-J Kim; M-S Park; K A Kim
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

6.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Authors:  Sith Phongkitkarun; Kuruwin Limsamutpetch; Penampai Tannaphai; Janjira Jatchavala
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 7.  Solid liver masses: approach to management from the standpoint of a radiologist.

Authors:  Robert Garrett
Journal:  Curr Gastroenterol Rep       Date:  2013-12

8.  Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.

Authors:  Megumi Matsuda; Takaharu Tsuda; Shinji Yoshioka; Shigetoshi Murata; Hiroaki Tanaka; Masashi Hirooka; Yoichi Hiasa; Teruhito Mochizuki
Journal:  Jpn J Radiol       Date:  2014-05-24       Impact factor: 2.374

Review 9.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

10.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.